Literature DB >> 17407158

Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways.

Supaporn Suttamanatwong1, Renny T Franceschi, Ann E Carlson, Rajaram Gopalakrishnan.   

Abstract

Inhibition of osteoblast-mediated mineralization is one of the major catabolic effects of parathyroid hormone (PTH) on bone. Previously, we showed that PTH induces matrix gamma-carboxyglutamic acid (Gla) protein (MGP) expression and established that this induction is critical for PTH-mediated inhibition of osteoblast mineralization. In the present study, we focus on the mechanism through which PTH regulates MGP expression in osteoblastic MC3T3-E1 cells. Following transient transfection of these cells with a -748 bp murine MGP promoter-luciferase construct (pMGP-luc), PTH (10 (-7) M) induced promoter activity in a time-dependent manner with a maximal four- to six fold induction seen 6 h after PTH treatment. Both H-89 (PKA inhibitor) and U0126 (MEK inhibitor), suppressed PTH induction of MGP promoter activity as well as the MGP mRNA level. In addition, forskolin (PKA activator) stimulated MGP promoter activity and mRNA levels confirming that PKA is one of the signaling molecules required for regulation of MGP by PTH. Co-transfection of MC3T3-E1 cells with pMGP-luc and MEK(SP), a plasmid encoding the constitutively active form of MEK, led to a dose-dependent increase in MGP promoter activity. Both MGP promoter activity and MGP mRNA level were not affected by the protein kinase C (PKC) inhibitor, GF109203X. However, phorbol 12-myristate 13-acetate (PMA), a selective PKC activator induced MGP mRNA expression through activation of extracellular signal-regulated kinase (ERK). Taken together, these results indicate that PTH regulates MGP via both PKA- and ERK-dependent pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407158     DOI: 10.1002/jcb.21314

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

Review 1.  Arterial calcification and bone physiology: role of the bone-vascular axis.

Authors:  Bithika Thompson; Dwight A Towler
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

2.  Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.

Authors:  Chandrika D Mahalingam; Tanuka Datta; Rashmi V Patil; Jaclynn Kreider; R Daniel Bonfil; Keith L Kirkwood; Steven A Goldstein; Abdul B Abou-Samra; Nabanita S Datta
Journal:  J Endocrinol       Date:  2011-08-18       Impact factor: 4.286

3.  Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.

Authors:  Liping Xiao; Takahiro Naganawa; Joseph Lorenzo; Thomas O Carpenter; J Douglas Coffin; Marja M Hurley
Journal:  J Biol Chem       Date:  2009-11-20       Impact factor: 5.157

4.  Sp proteins and Runx2 mediate regulation of matrix gla protein (MGP) expression by parathyroid hormone.

Authors:  Supaporn Suttamanatwong; Eric D Jensen; Jody Schilling; Renny T Franceschi; Ann E Carlson; Kim C Mansky; Rajaram Gopalakrishnan
Journal:  J Cell Biochem       Date:  2009-05-15       Impact factor: 4.429

5.  Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice.

Authors:  Quan Yuan; Tadatoshi Sato; Michael Densmore; Hiroaki Saito; Christiane Schüler; Reinhold G Erben; Beate Lanske
Journal:  PLoS Genet       Date:  2012-05-17       Impact factor: 5.917

6.  Different duration of parathyroid hormone exposure distinctively regulates primary response genes Nurr1 and RANKL in osteoblasts.

Authors:  Hyewon Choi; Clara E Magyar; Jeanne M Nervina; Sotirios Tetradis
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

Review 7.  Protein tyrosine phosphatases in skeletal development and diseases.

Authors:  Huiliang Yang; Lijun Wang; Christian Shigley; Wentian Yang
Journal:  Bone Res       Date:  2022-01-28       Impact factor: 13.567

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.